DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 9,552.457 B2 Jones Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 9,552.457 B2 Jones Et Al USO09552457B2 (12) United States Patent (10) Patent No.: US 9,552.457 B2 Jones et al. (45) Date of Patent: Jan. 24, 2017 (54) REPROGRAMMING EFFECTOR PROTEIN A61 K3I/4709 (2013.01); A61 K3I/5375 INTERACTIONS TO CORRECT (2013.01); C40B 30/02 (2013.01); G06F EPGENETIC DEFECTS IN CANCER 19/706 (2013.01) (58) Field of Classification Search (71) Applicant: BRITISH COLUMBIA CANCER None AGENCY BRANCH, Vancouver (CA) See application file for complete search history. (72) Inventors: Steven J. M. Jones, Vancouver (CA); Oleksandr Yakovenko, Vancouver (56) References Cited (CA); Silvia Thoene, Vancouver (CA); Pierre Yulmin Cheung, Vancouver U.S. PATENT DOCUMENTS (CA); Jianghong An, Vancouver (CA) 3,257.274 A 6/1966 Loprieno et al. 3,466,274 A 9, 1969 De Ridder (73) Assignee: BRITISH COLUMBIA CANCER 3,622,580 A 11/1971 Hromatka et al. AGENCY BRANCH, Vancouver (CA) 2009/O137508 A1 5/2009 McSwiggen et al. 2011/0237606 A1 9, 2011 Chai et al. (*) Notice: Subject to any disclaimer, the term of this 2011 O251216 A1 10/2011 Chinnaiyan et al. patent is extended or adjusted under 35 2012,007 1418 A1 3/2012 Copeland et al. U.S.C. 154(b) by 0 days. FOREIGN PATENT DOCUMENTS (21) Appl. No.: 14/381,588 CA WO 2013059944 5, 2013 EP O156785 A1 10, 1985 (22) PCT Filed: Feb. 27, 2013 EP WO2012O123119 A1 9, 2012 GB WO 2010.064019 6, 2010 (86). PCT No.: PCT/CA2O13/OSO145 WO 2007136790 A2 11/2007 WO WO2O09015283 A2 1, 2009 S 371 (c)(1), WO WO 2010O45199 4/2010 (2) Date: Aug. 27, 2014 WO WO 2010094009 8, 2010 WO WO 2011014825 2, 2011 WO WO2O110 143669 A2 11/2011 (87) PCT Pub. No.: WO2013/127011 WO WO2012O71469 A2 5, 2012 PCT Pub. Date: Sep. 6, 2013 WO WO2012O116170 A1 8, 2012 (65) Prior Publication Data OTHER PUBLICATIONS US 2015/O1543.45 A1 Jun. 4, 2015 Mund et al. Bioassays, 32: 949-957, 2010.* New Zealand Intellectual Property Office, Office Action issued in Related U.S. Application Data New Zealand Patent Application No. 700058, Aug. 17, 2015, 4 pageS. (60) Provisional application No. 61/637.282, filed on Apr. European Patent Office, Search Report issued in European Patent 24, 2012, provisional application No. 61/603,650, Application No. 13754077.9. Sep. 25, 2015, 6 pages. filed on Feb. 27, 2012. Santiago, C., et al., “Druggability of Methyl-Lysine Binding Sites.” Journal of Computer-Aided Molecular Design, vol. 25, No. 12, Dec. (51) Int. Cl. 7, 2011, pp. 1171-1178. G06F 9/16 (2011.01) (Continued) A6 IK3I/37 (2006.01) A6 IK 3/47 (2006.01) A6 IK 3/46 (2006.01) Primary Examiner — Michael Borin A6 IK3I/It (2006.01) (74) Attorney, Agent, or Firm — Laura M. Lloyd: Leech A6 IK3I/35 (2006.01) Tishman Fuscaldo & Lampl A6 IK3I/I67 (2006.01) A6 IK 3L/245 (2006.01) A6 IK3I/36 (2006.01) (57) ABSTRACT A6 IK 3/407 (2006.01) Methods of “reprogramming epigenetic mark readers or A 6LX 3/5.375 (2006.01) erasers to recognize epigenetic marks other than their cog C4OB 30/02 (2006.01) nate (or natural) marks are provided. Reprogramming the G06F 9/00 (2011.01) reader or eraser can offset the effects of aberrant writer A6 IK3I/343 (2006.01) activity (for example, loss of function or overactivity) that A 6LX 3L/24709 (2006.01) can contribute to certain diseases states, such as cancer. The (52) U.S. Cl. use of the reprogramming compounds identified by these CPC ............... G06F 19/16 (2013.01); A61 K3I/10 methods in the treatment of Such disease states is also (2013.01); A61K 31/135 (2013.01); A61 K provided. Exemplary mark readers that can be targeted by 3 1/137 (2013.01); A61K 3 1/167 (2013.01); these methods include BPTF and CBX2. A6 IK3I/245 (2013.01); A61K 3 1/343 (2013.01); A61 K3I/36 (2013.01); A61 K 31/407 (2013.01); A61 K3I/47 (2013.01); 13 Claims, 14 Drawing Sheets US 9,552.457 B2 Page 2 (56) References Cited Morin, et al., “Somatic mutation of EZH2 (Y641) in Follicular and Diffuse Large B-cell Lymphomas of Germinal Center Origin.” 2010, Nat. Genet., 42(2): 181-185, NIH. OTHER PUBLICATIONS Musselman, C. A. et al., “PHD fingers: epigenetic effectors and Lutz, Robert E., et al., “Antimalarials C-Alkyl and potential drug targets'. Mol. Interv. Dec. 2009, 9 (6), 314-323. Dialkylaminomethyl-2-phenyl-4-quinolinemethanols”, Journal of Ng, S. S. et al., “Dynamic protein methylation in chromatin biol the American Chemical Society, vol. 68, No. 9, Sep. 1, 1946, pp. ogy”. Cell. Mol. Life Sci., Feb. 2009, 66 (3), 407-422. 1813-1831. Nose, S. et al., "Constant pressure molecular dynamics for molecu Berendsen, H. et al., “Interaction Models for Water in Relation to lar systems.” Mol. Phys. 1983, 50:1055-1076. Protein Hydration.” B. Pullman (ed.), Intermolecular Forces, 1981 Nose, S., “A molecular dynamics method for simulations in the pp. 331-342, D. Reidel Publishing Company. canonical ensemble.” Mol. Phys. 2002, 100:191-198, Taylor & Berendsen, H. J. C. et al., “Molecular dynamics with coupling to Francis Ltd. an external bath,” J. Chem. Phys. 181 (8), Oct. 15, 1984, pp. Parrinello, M. et al., “Polymorphic transitions in single crystals: A 3684-3690, American Institute of Physics. new molecular dynamics method.” J. Appl. Phys. 1981, 52:7182 Campagna-Slater, V. et al., “Pharmacophore Screening of the Pro T190. tein Data Bank for Specific Binding Aite Chemistry”. J. Chem. Inf. Pasqualucci, L. et al., “Analysis of the coding genome of diffuse Model. Mar. 2010, 50 (3), pp. 358-367, American Chemical Soci large B-cell lymphoma,” Nat. Genet. Jul. 31, 2011; 43(9):830-837. ety. Nature America, Inc. Cerny, V., “Thermodynamic Approach to the Traveling Salesman Pati, H.N. et al., "o-Substituted I-Aryl-3-dimethylaminopropanone Problem: An Efficient Simulation Algorithm.” JOTA vol. 45, No. 1, Hydrochlorides: Potent Cytotoxins towards Human WilDr Colon Jan. 1985, pp. 41-51. Plenum Publishing Corporation. Cancer Cells', Chemical & Pharmaceutical Bulletin, 2007, 55(4), Dimmock, J. R., et al., “Cytotoxic and anticancer activities of 511-515, Pharmaceutical Society of Japan. Somel-aryl-2-dimethylaminomethyl-2-propen-I-one hydrochlo Quinn, A. M. et al., “Methods for Activity Analysis of the Proteins rides”, Pharmazie, 1998, 53(10), 702-706. that Regulate Histone Methylation'. Current Chemical Genomics. Essmann, U. et al., “A Smooth particle mesh Ewald method.” J. 2011, 5 (Suppl. I-M6), 95-105, Bentham Open. Chem. Phys. 1995, 103.8577-8593. Rotili. D. and Mai, A., “Targeting Histone Demthylases: A Newe Grauffel, C. et al., “Force field parameters for the simulation of Avenue for the Fight Against Cancer.” 2011, Genes & Cancer, modified histone tails”. J. Comput. Chem. Oct. 2010, 31 (13), pp. 2:663-679. 2434-2451, Wiley Periodicals, Inc. Ruthenburg et al., “Recognition of a mononucleosomal histone Gui, et al., “Frequent mutations of chromatin remodeling genes in modification pattern by BPTF via multivalent interactions.” 2011, transitional cell carcinoma of the bladder,’ 2011, Nat. Genet. Cell, 145(5):692-706, Elsevier, Inc. 43:875-878. Schuttelkopf, A. W. et al., “PRODRG: a tool for high-throughput Herold, J. M. et al., “Drug discovery toward antagonists of methyl crystallography of protein-ligand complexes.” Acta Cryst. D Biol. lysine binding proteins”. Current Chem. Genomics, Aug. 2011, 5 Crystallography 2004, 60:1355-1363, International Union of Crys (Suppl-M2), pp. 51-61, Bentham Open. tallography. Hoover, W. “Canonical dynamics: Equilibrium phase-space distri Scott, W. et al., “The GROMOS Biomolecular Simulation Program butions.” Physical Review. A 1985, 31: 1695-1697. The American Package.” J. Phys. Chem. A 1999, 103, 3596-3607, American Physical Society. Chemical Society. Humphrey, W.; et al., “VMD: Visual Molecular Dynamics,” J. Mol. Sneeringer, et al., "Coordinated activities of wild-type plus mutant Graph. 1996, 14:33-8, 27-8. Elsevier Science Inc. EZH2 drive tumor-associated hypertrimethylation of lysine 27 on Kaustov, L. et al., “Recognition and specificity determinants of the histone H3 (H3K27) in human B-cell lymphomas,” 2010, Proc. human CbX chromodomains”, Journal of Biological Chemistry, Jan. Natl. Acad. Sci. U. S. A., 107:20980-20985, Epizyme, Inc. 7, 2011, 286 (1), 521-529. Watanabe, et al., “Frequent Alteration of MLL3 Frameshift Muta Kirkpatrick, S. et al., "Optimization by Simulated Annealing.” tions in Microsatellite Deficient Colorectal Cancer,’ PLoS One, Science 1983, 220:671-680. Aug. 2011, vol. 6, Issue 8, e23320, pp. 1-8. Kunkel, M.W. et al., “Cell line-directed screening assay for inhibi Yap, et al., “Somatic mutations at EZH2 Y641 act dominantly tors of thioredoxin reductase signaling as potential anti-cancer through a mechanism of selectively altered PRC2 catalytic activity, drugs' Anti-Cancer Drug Design, 1997. 12(8), 659-670, Oxford to increase H3K27 trimethylation.” Blood, Feb. 24, 2011, vol. 117. University Press. No. 8, pp. 2451-2459. The American Society of Hematology. Lemkul. J. A. et al., “Practical Considerations for Building Ziemin-Van Der Poel, et al., “Identification of a gene, MML, that GROMOS-Compatible Small Molecule Topologies,” J. Chem. Inf. spans the breakpoint in 11q23 translocations associated with human Model. 2010, 50:2221-2235, American Chem. Society. leukemias.” Proc. Natl. Acad. Sci. USA vol. 88, pp. 10735-10739, Li H., et al., “Structural Basis for Lower Lysine Methylation Dec. 1991 Medical Sciences. State-Specific Readout by MBT Repeats of L3MBTL1 and an British Columbia Cancer Agency Branch, International Search Engineered PHD Finger.” 2007, Mol. Cell., 28:677-691, Elsevier Report and Written Opinion of the International Searching Author Inc. ity, International Patent Application No. PCT/CA2013/050145, Li, H., et al., “Molecular basis for site-specific read-out of histone Canadian Intellectual Property Office, May 27, 2013.
Load more

Recommended publications
  • Cooperativity of Imprinted Genes Inactivated by Acquired Chromosome 20Q Deletions
    Cooperativity of imprinted genes inactivated by acquired chromosome 20q deletions Athar Aziz, … , Anne C. Ferguson-Smith, Anthony R. Green J Clin Invest. 2013;123(5):2169-2182. https://doi.org/10.1172/JCI66113. Research Article Oncology Large regions of recurrent genomic loss are common in cancers; however, with a few well-characterized exceptions, how they contribute to tumor pathogenesis remains largely obscure. Here we identified primate-restricted imprinting of a gene cluster on chromosome 20 in the region commonly deleted in chronic myeloid malignancies. We showed that a single heterozygous 20q deletion consistently resulted in the complete loss of expression of the imprinted genes L3MBTL1 and SGK2, indicative of a pathogenetic role for loss of the active paternally inherited locus. Concomitant loss of both L3MBTL1 and SGK2 dysregulated erythropoiesis and megakaryopoiesis, 2 lineages commonly affected in chronic myeloid malignancies, with distinct consequences in each lineage. We demonstrated that L3MBTL1 and SGK2 collaborated in the transcriptional regulation of MYC by influencing different aspects of chromatin structure. L3MBTL1 is known to regulate nucleosomal compaction, and we here showed that SGK2 inactivated BRG1, a key ATP-dependent helicase within the SWI/SNF complex that regulates nucleosomal positioning. These results demonstrate a link between an imprinted gene cluster and malignancy, reveal a new pathogenetic mechanism associated with acquired regions of genomic loss, and underline the complex molecular and cellular consequences of “simple” cancer-associated chromosome deletions. Find the latest version: https://jci.me/66113/pdf Research article Cooperativity of imprinted genes inactivated by acquired chromosome 20q deletions Athar Aziz,1,2 E. Joanna Baxter,1,2,3 Carol Edwards,4 Clara Yujing Cheong,5 Mitsuteru Ito,4 Anthony Bench,3 Rebecca Kelley,1,2 Yvonne Silber,1,2 Philip A.
    [Show full text]
  • Genome-Wide Parent-Of-Origin DNA Methylation Analysis Reveals The
    Downloaded from genome.cshlp.org on September 25, 2021 - Published by Cold Spring Harbor Laboratory Press Research Genome-wide parent-of-origin DNA methylation analysis reveals the intricacies of human imprinting and suggests a germline methylation-independent mechanism of establishment Franck Court,1,15 Chiharu Tayama,2,15 Valeria Romanelli,1,15 Alex Martin-Trujillo,1,15 Isabel Iglesias-Platas,3 Kohji Okamura,4 Naoko Sugahara,2 Carlos Simo´n,5 Harry Moore,6 Julie V. Harness,7 Hans Keirstead,7 Jose Vicente Sanchez-Mut,8 Eisuke Kaneki,9 Pablo Lapunzina,10 Hidenobu Soejima,11 Norio Wake,9 Manel Esteller,8,12,13 Tsutomu Ogata,14 Kenichiro Hata,2 Kazuhiko Nakabayashi,2,16,17 and David Monk1,16,17 1–14[Author affiliations appear at the end of the paper.] Differential methylation between the two alleles of a gene has been observed in imprinted regions, where the methylation of one allele occurs on a parent-of-origin basis, the inactive X-chromosome in females, and at those loci whose methylation is driven by genetic variants. We have extensively characterized imprinted methylation in a substantial range of normal human tissues, reciprocal genome-wide uniparental disomies, and hydatidiform moles, using a combination of whole- genome bisulfite sequencing and high-density methylation microarrays. This approach allowed us to define methylation profiles at known imprinted domains at base-pair resolution, as well as to identify 21 novel loci harboring parent-of-origin methylation, 15 of which are restricted to the placenta. We observe that the extent of imprinted differentially methylated regions (DMRs) is extremely similar between tissues, with the exception of the placenta.
    [Show full text]
  • Investigation of Candidate Genes and Mechanisms Underlying Obesity
    Prashanth et al. BMC Endocrine Disorders (2021) 21:80 https://doi.org/10.1186/s12902-021-00718-5 RESEARCH ARTICLE Open Access Investigation of candidate genes and mechanisms underlying obesity associated type 2 diabetes mellitus using bioinformatics analysis and screening of small drug molecules G. Prashanth1 , Basavaraj Vastrad2 , Anandkumar Tengli3 , Chanabasayya Vastrad4* and Iranna Kotturshetti5 Abstract Background: Obesity associated type 2 diabetes mellitus is a metabolic disorder ; however, the etiology of obesity associated type 2 diabetes mellitus remains largely unknown. There is an urgent need to further broaden the understanding of the molecular mechanism associated in obesity associated type 2 diabetes mellitus. Methods: To screen the differentially expressed genes (DEGs) that might play essential roles in obesity associated type 2 diabetes mellitus, the publicly available expression profiling by high throughput sequencing data (GSE143319) was downloaded and screened for DEGs. Then, Gene Ontology (GO) and REACTOME pathway enrichment analysis were performed. The protein - protein interaction network, miRNA - target genes regulatory network and TF-target gene regulatory network were constructed and analyzed for identification of hub and target genes. The hub genes were validated by receiver operating characteristic (ROC) curve analysis and RT- PCR analysis. Finally, a molecular docking study was performed on over expressed proteins to predict the target small drug molecules. Results: A total of 820 DEGs were identified between
    [Show full text]
  • Imprinting of the Human L3MBTL Gene, a Polycomb Family Member Located in a Region of Chromosome 20 Deleted in Human Myeloid Malignancies
    Correction GENETICS Correction for “Imprinting of the human L3MBTL gene, a poly- The authors note that a mistake occurred during the prepa- comb family member located in a region of chromosome 20 deleted ration of Fig. 1B. Three control lanes (6, 7, and 8) were inad- in human myeloid malignancies,” by Juan Li, Anthony J. Bench, vertently duplicated and also shown as lanes 3, 4, and 5. This George S. Vassiliou, Nasios Fourouclas, Anne C. Ferguson-Smith, resulted from a technical error during preparation of the figure and Anthony R. Green, first published April 30, 2004; 10.1073/ and does not alter any of the conclusions of the paper. The pnas.0308195101 (Proc. Natl. Acad. Sci. U.S.A. 101, 7341–7346). corrected figure and the unaltered figure legend appear below. A CORRECTION B C Fig. 1. Allelic methylation of the L3MBTL gene. (A) Locus of the L3MBTL gene and intron/exon structure of its 5′ and 3′ regions. Coding and noncoding exons are shown in black and gray boxes, respectively. Bent arrows indicate two putative promoters. Patterned horizontal bars represent the four CpG islands. Asterisks indicate the locations of SNPs used in the study, and primers spanning the respective SNPs are indicated (P1–P8). (B) Methylation analysis of the CpG island 3 by using SSCP. Lane 1, universally methylated genomic control DNA; lanes 2–5, normal bone marrow; lanes 6–9, normal granulocytes; lanes 10–13, granulocytes from patients, with an acquired 20q deletion. (C) Bisulfite sequencing of CpG island 3. Sequences relate to samples corresponding to individual lanes from B, as indicated.
    [Show full text]
  • 1 Inventory of Supplemental Information Presented in Relation To
    Inventory of Supplemental Information presented in relation to each of the main figures in the manuscript 1. Figure S1. Related to Figure 1. 2. Figure S2. Related to Figure 2. 3. Figure S3. Related to Figure 3. 4. Figure S4. Related to Figure 4. 5. Figure S5. Related to Figure 5. 6. Figure S6. Related to Figure 6. 7. Figure S7. Related to Figure 7. 8. Table S1. Related to Figures 1 and S1. 9. Table S2. Related to Figures 3, 4, 6 and 7. 10. Table S3. Related to Figure 3. Supplemental Experimental Procedures 1. Patients and samples 2. Cell culture 3. Long term culture-initiating cells (LTC-IC) assay 4. Differentiation of CD34+ cord blood cells 5. Bi-phasic erythroid differentiation assay 6. Clonal assay 7. Mutation and sequencing analysis 8. Bisulphite sequencing and quantitative pyrosequencing 9. Human SNP genotyping 10. Strand-specific cDNA synthesis and PCR 11. Chromatin Immuno-precipitation (ChIP) 12. Immunoprecipitation and western blot 13. Colony genotyping 14. shRNA generation and viral infection 15. Retrovirus generation and transduction 16. Study approval 17. Statistical Methods 18. Primers list Supplementary References (19) 1 Additional SGK2 families 2 3 4 ♂ ♀ ♂ ♀ ♂ ♀ C/G C/C C/C C/G C/C C/G ♀ ♀ ♂ ♀ C/G C/G C/G C/G T T C T G C T A G A T T C T C C T A G A T T C T C C T A G A T T C T C C T A G A T-Cells T-Cells T-Cells T-Cells Additional GDAP1L1 familiy 2 ♂ ♀ G/G A/A ♀ G/A A C A C G G T G Erythroblasts Figure S1 - .
    [Show full text]
  • Proteomic Expression Profile in Human Temporomandibular Joint
    diagnostics Article Proteomic Expression Profile in Human Temporomandibular Joint Dysfunction Andrea Duarte Doetzer 1,*, Roberto Hirochi Herai 1 , Marília Afonso Rabelo Buzalaf 2 and Paula Cristina Trevilatto 1 1 Graduate Program in Health Sciences, School of Medicine, Pontifícia Universidade Católica do Paraná (PUCPR), Curitiba 80215-901, Brazil; [email protected] (R.H.H.); [email protected] (P.C.T.) 2 Department of Biological Sciences, Bauru School of Dentistry, University of São Paulo, Bauru 17012-901, Brazil; [email protected] * Correspondence: [email protected]; Tel.: +55-41-991-864-747 Abstract: Temporomandibular joint dysfunction (TMD) is a multifactorial condition that impairs human’s health and quality of life. Its etiology is still a challenge due to its complex development and the great number of different conditions it comprises. One of the most common forms of TMD is anterior disc displacement without reduction (DDWoR) and other TMDs with distinct origins are condylar hyperplasia (CH) and mandibular dislocation (MD). Thus, the aim of this study is to identify the protein expression profile of synovial fluid and the temporomandibular joint disc of patients diagnosed with DDWoR, CH and MD. Synovial fluid and a fraction of the temporomandibular joint disc were collected from nine patients diagnosed with DDWoR (n = 3), CH (n = 4) and MD (n = 2). Samples were subjected to label-free nLC-MS/MS for proteomic data extraction, and then bioinformatics analysis were conducted for protein identification and functional annotation. The three Citation: Doetzer, A.D.; Herai, R.H.; TMD conditions showed different protein expression profiles, and novel proteins were identified Buzalaf, M.A.R.; Trevilatto, P.C.
    [Show full text]
  • Detailed Characterization of Human Induced Pluripotent Stem Cells Manufactured for Therapeutic Applications
    Stem Cell Rev and Rep DOI 10.1007/s12015-016-9662-8 Detailed Characterization of Human Induced Pluripotent Stem Cells Manufactured for Therapeutic Applications Behnam Ahmadian Baghbaderani 1 & Adhikarla Syama2 & Renuka Sivapatham3 & Ying Pei4 & Odity Mukherjee2 & Thomas Fellner1 & Xianmin Zeng3,4 & Mahendra S. Rao5,6 # The Author(s) 2016. This article is published with open access at Springerlink.com Abstract We have recently described manufacturing of hu- help determine which set of tests will be most useful in mon- man induced pluripotent stem cells (iPSC) master cell banks itoring the cells and establishing criteria for discarding a line. (MCB) generated by a clinically compliant process using cord blood as a starting material (Baghbaderani et al. in Stem Cell Keywords Induced pluripotent stem cells . Embryonic stem Reports, 5(4), 647–659, 2015). In this manuscript, we de- cells . Manufacturing . cGMP . Consent . Markers scribe the detailed characterization of the two iPSC clones generated using this process, including whole genome se- quencing (WGS), microarray, and comparative genomic hy- Introduction bridization (aCGH) single nucleotide polymorphism (SNP) analysis. We compare their profiles with a proposed calibra- Induced pluripotent stem cells (iPSCs) are akin to embryonic tion material and with a reporter subclone and lines made by a stem cells (ESC) [2] in their developmental potential, but dif- similar process from different donors. We believe that iPSCs fer from ESC in the starting cell used and the requirement of a are likely to be used to make multiple clinical products. We set of proteins to induce pluripotency [3]. Although function- further believe that the lines used as input material will be used ally identical, iPSCs may differ from ESC in subtle ways, at different sites and, given their immortal status, will be used including in their epigenetic profile, exposure to the environ- for many years or even decades.
    [Show full text]
  • Cellular Functions of Genetically Imprinted Genes in Human and Mouse As Annotated in the Gene Ontology
    Cellular Functions of Genetically Imprinted Genes in Human and Mouse as Annotated in the Gene Ontology Mohamed Hamed1, Siba Ismael1, Martina Paulsen2, Volkhard Helms1* 1 Center for Bioinformatics, Saarland University, Saarbru¨cken, Germany, 2 Department of Genetics, Saarland University, Saarbru¨cken, Germany Abstract By analyzing the cellular functions of genetically imprinted genes as annotated in the Gene Ontology for human and mouse, we found that imprinted genes are often involved in developmental, transport and regulatory processes. In the human, paternally expressed genes are enriched in GO terms related to the development of organs and of anatomical structures. In the mouse, maternally expressed genes regulate cation transport as well as G-protein signaling processes. Furthermore, we investigated if imprinted genes are regulated by common transcription factors. We identified 25 TF families that showed an enrichment of binding sites in the set of imprinted genes in human and 40 TF families in mouse. In general, maternally and paternally expressed genes are not regulated by different transcription factors. The genes Nnat, Klf14, Blcap, Gnas and Ube3a contribute most to the enrichment of TF families. In the mouse, genes that are maternally expressed in placenta are enriched for AP1 binding sites. In the human, we found that these genes possessed binding sites for both, AP1 and SP1. Citation: Hamed M, Ismael S, Paulsen M, Helms V (2012) Cellular Functions of Genetically Imprinted Genes in Human and Mouse as Annotated in the Gene Ontology. PLoS ONE 7(11): e50285. doi:10.1371/journal.pone.0050285 Editor: Osman El-Maarri, University of Bonn, Institut of experimental hematology and transfusion medicine, Germany Received June 23, 2012; Accepted October 23, 2012; Published November 30, 2012 Copyright: ß 2012 Hamed et al.
    [Show full text]
  • The DNA Sequence and Comparative Analysis of Human Chromosome 20
    articles The DNA sequence and comparative analysis of human chromosome 20 P. Deloukas, L. H. Matthews, J. Ashurst, J. Burton, J. G. R. Gilbert, M. Jones, G. Stavrides, J. P. Almeida, A. K. Babbage, C. L. Bagguley, J. Bailey, K. F. Barlow, K. N. Bates, L. M. Beard, D. M. Beare, O. P. Beasley, C. P. Bird, S. E. Blakey, A. M. Bridgeman, A. J. Brown, D. Buck, W. Burrill, A. P. Butler, C. Carder, N. P. Carter, J. C. Chapman, M. Clamp, G. Clark, L. N. Clark, S. Y. Clark, C. M. Clee, S. Clegg, V. E. Cobley, R. E. Collier, R. Connor, N. R. Corby, A. Coulson, G. J. Coville, R. Deadman, P. Dhami, M. Dunn, A. G. Ellington, J. A. Frankland, A. Fraser, L. French, P. Garner, D. V. Grafham, C. Grif®ths, M. N. D. Grif®ths, R. Gwilliam, R. E. Hall, S. Hammond, J. L. Harley, P. D. Heath, S. Ho, J. L. Holden, P. J. Howden, E. Huckle, A. R. Hunt, S. E. Hunt, K. Jekosch, C. M. Johnson, D. Johnson, M. P. Kay, A. M. Kimberley, A. King, A. Knights, G. K. Laird, S. Lawlor, M. H. Lehvaslaiho, M. Leversha, C. Lloyd, D. M. Lloyd, J. D. Lovell, V. L. Marsh, S. L. Martin, L. J. McConnachie, K. McLay, A. A. McMurray, S. Milne, D. Mistry, M. J. F. Moore, J. C. Mullikin, T. Nickerson, K. Oliver, A. Parker, R. Patel, T. A. V. Pearce, A. I. Peck, B. J. C. T. Phillimore, S. R. Prathalingam, R. W. Plumb, H. Ramsay, C. M.
    [Show full text]
  • Ranking Genes by Their Co-Expression to Subsets of Pathway Members
    THE CHALLENGES OF SYSTEMS BIOLOGY Ranking Genes by Their Co-expression to Subsets of Pathway Members a, a,c, b Priit Adler, § Hedi Peterson, § Phaedra Agius, Juri¨ Reimand,b,d and Jaak Vilob,c aInstitute of Molecular and Cell Biology, University of Tartu, Tartu, Estonia bInstitute of Computer Science, University of Tartu, Tartu, Estonia cQuretec Ltd., Tartu, Estonia dEMBL Outstation, European Bioinformatics Institute, Wellcome Trust Genome Campus, Hinxton, United Kingdom Cellular processes are often carried out by intricate systems of interacting genes and proteins. Some of these systems are rather well studied and described in pathway databases, while the roles and functions of the majority of genes are poorly understood. A large compendium of public microarray data is available that covers a variety of con- ditions, samples, and tissues and provides a rich source for genome-scale information. We focus our study on the analysis of 35 curated biological pathways in the context of gene co-expression over a large variety of biological conditions. By defining a global co-expression similarity rank for each gene and pathway, we perform exhaustive leave- one-out computations to describe existing pathway memberships using other members of the corresponding pathway as reference. We demonstrate that while successful in recovering biological base processes such as metabolism and translation, the global correlation measure fails to detect gene memberships in signaling pathways where co- expression is less evident. Our results also show that pathway membership detection is more effective when using only a subset of corresponding pathway members as ref- erence, supporting the existence of more tightly co-expressed subsets of genes within pathways.
    [Show full text]
  • L3MBTL1 Polycomb Protein, a Candidate Tumor Suppressor in Del(20Q12) Myeloid Disorders, Is Essential for Genome Stability
    L3MBTL1 polycomb protein, a candidate tumor suppressor in del(20q12) myeloid disorders, is essential for genome stability Nadia Gurvicha, Fabiana Pernaa, Andrea Farinab, Francesca Vozaa, Silvia Menendeza, Jerard Hurwitzb, and Stephen D. Nimera,1 aMolecular Pharmacology and Chemistry Program and bMolecular Biology Program, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, NY 10065 Contributed by Jerard Hurwitz, November 17, 2010 (sent for review August 2, 2010) The l3mbtl1 gene is located on the long arm of chromosome 20 erate mutations and/or chromosomal translocations that can (q12), within a region commonly deleted in several myeloid malig- promote tumorigenesis (9). DNA breaks resulting from replica- nancies. L3MBTL1 is a human homolog of the Drosophila polycomb tive stress trigger an ATM/ATR-dependent DNA damage re- L(3)MBT tumor suppressor protein and thus a candidate tumor sup- sponse (DDR), which prevents the proliferation of cells with pressor in del(20q12) myeloid disorders. We used the loss-of-func- damaged DNA by inducing either cell cycle arrest or apoptosis. tion approach to explore the possible tumor suppressive mecha- An activated DDR is present in precancerous lesions from tis- nism of L3MBTL1 and found that depletion of L3MBTL1 from sues of different origins, and many overexpressed oncogenes human cells causes replicative stress, DNA breaks, activation of cause replicative stress and activation of the DDR. When cou- the DNA damage response, and genomic instability. L3MBTL1 pled with mutations in checkpoint and/or DNA repair genes, interacts with Cdc45, MCM2-7 and PCNA, components of the these abnormalities can lead to cancer (10–12).
    [Show full text]
  • BMC Proceedings Biomed Central
    BMC Proceedings BioMed Central Research Open Access Pathway results from the chicken data set using GOTM, Pathway Studio and Ingenuity softwares Agnès Bonnet1, Sandrine Lagarrigue2,3, Laurence Liaubet1, Christèle Robert- Granié4, Magali SanCristobal1 and Gwenola Tosser-Klopp*1 Address: 1INRA, UMR444, Laboratoire de Génétique Cellulaire, F-31326 Castanet-Tolosan, France, 2INRA, UMR 598, Génétique Animale, F-35000 Rennes, France, 3Agrocampus Ouest, UMR 598 Génétique Animale, F-35000 Rennes, France and 4INRA, UR631, Station d'Amélioration Génétique des Animaux, F-31326 Castanet-Tolosan, France Email: Agnès Bonnet - [email protected]; Sandrine Lagarrigue - [email protected]; Laurence Liaubet - [email protected]; Christèle Robert-Granié - [email protected]; Magali SanCristobal - [email protected]; Gwenola Tosser-Klopp* - [email protected] * Corresponding author from EADGENE and SABRE Post-analyses Workshop Lelystad, The Netherlands. 12–14 November 2008 Published: 16 July 2009 BMC Proceedings 2009, 3(Suppl 4):S11 doi:10.1186/1753-6561-3-S4-S11 <supplement> <title> <p>EADGENE and SABRE Post-analyses Workshop</p> </title> <editor>Dirk-Jan de Koning</editor> <sponsor> <note>The publication of these proceedings was supported by the EC-funded Network of Excellence EADGENE (EC contract number FOOD-CT-2004-506416).</note> </sponsor> <note>Proceedings</note> <url>http://www.biomedcentral.com/content/pdf/1753-6561-3-S4-info.pdf</url> </supplement> This article is available from: http://www.biomedcentral.com/1753-6561/3/S4/S11 © 2009 Bonnet et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
    [Show full text]